The inclusion of six population-based cohorts from diverse geographical settings enhances the generalizability of the findings. The authors also remarked that, The median follow-up period of 1.8 to 3.0 years is insufficient to evaluate long-term risks. In addition, the studys focus on populations with type 2 diabetes may limit is applicability to non-diabetic populations, a growing group of GLP-1RA users, particularly for obesity management. About the Journal Thyroid , the official journal of the American Thyroid Association , (ATA ) is an authoritative peer-reviewed journal published monthly online with open access options and in print
SM is also a consultant for Netdoktor and has served as principal investigator in relation to the development of drugs for the treatment of type 2 diabetes and obesity in collaboration with Novo Nordisk and Bayer, with funds paid to the institution where he is employed, with no personal fee and with no relation to the work reported in this article
It is solely your responsibility to verify this information before making decisions or incurring costs based on such information
doi: 10.1111/bcp.15209
[DOI] [PMC free article] [PubMed] [Google Scholar] 101.Secher A, Jelsing J, Baquero AF, Hecksher-Srensen J, Cowley MA, Dalbge LS
Its important to note that results will not be immediate, as the appetite-suppressing effects of semaglutide GLP-1 develop gradually
